Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 2.300

+0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Neil H who wrote (1738)	11/19/2003 1:24:26 PM
From: Jim Oravetz	of 1870

Preclinical Studies Demonstrate Activity Of Genasense DOW JONES NEWSWIRES BERKELEY HEIGHTS, N.J. -- Three preclinical trial studies show Genta Inc.'s (GNTA) anticancer drug Genasense enhances other cancer therapy. Genasense inhibits production the cancer protein Bcl-2, which is believed to contribute to cancer cells resisting treatment. In a press release Wednesday, the biopharmaceutical company said one study showed radiation therapy caused more prostate cancer cells to die when combined with Genasense. Another study showed increased radiation-induced cell death in melanoma, lung cancer and prostate cancer cell lines when additionally treated with Genasense. A third study showed Genasense inhibited Bcl-2 and reported increased cell death in various breast cancer cells lines without chemotherapy. In September, Genta said it expected to complete filing Genasense's application by the fourth quarter. A spokesperson wasn't immediately available for comment. Shares of Genasense recently traded at $9.25, up 31 cents, or 3.5%. Company Web site: genta.com -Jerry Abejo; Dow Jones Newswires; 201-938

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next